Viatris. has been granted a patent for a pharmaceutical formulation designed for topical otic, ophthalmic, or nasal use. The formulation includes a corticosteroid, xanthan gum, a chelating agent, and an ionic tonicity agent, achieving specific viscosity, osmolality, and pH levels, while ensuring redispersibility. GlobalData’s report on Viatris gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Viatris, Cancer treatment biomarkers was a key innovation area identified from patents. Viatris's grant share as of July 2024 was 58%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12023344B2 outlines a pharmaceutical formulation designed for topical otic, ophthalmic, or nasal applications. The formulation comprises a corticosteroid (ranging from 0.001% to 5% w/v), xanthan gum (0.3% to 1.5% w/v), an ionic tonicity agent (0.001% to 2% w/v), and a chelating agent, specifically ethylenediaminetetraacetic acid (EDTA) (0.2% to 2% w/v), with water as the balance. Key characteristics of the formulation include an osmolality between 250 to 350 mOsm, viscosity ranging from 4000 to 8000 centipoises, and a pH of 5 to 6. Additionally, the formulation is designed to be redispersible within 60 seconds, enhancing its usability.
Further claims detail the inclusion of nonionic surfactants and tonicity agents, with specific examples such as tyloxapol and propylene glycol. The patent also specifies formulations with prednisolone as the corticosteroid, sodium chloride as the ionic tonicity agent, and outlines precise concentration ranges for each component. The method of treatment described involves administering the formulation to patients with steroid-responsive ocular disorders, with dosages ranging from 10 µl to 200 µl, and frequency of administration from once daily to eight times per day over a period of one to twenty-one days. This patent presents a comprehensive approach to formulating and administering corticosteroid-based treatments for various topical applications.
To know more about GlobalData’s detailed insights on Viatris, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
